Queen Elizabeth University Hospital
Glasgow, United Kingdom
Location status: Recruiting
NCT Number: NCT07372508
Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier.
Additional tests undertaken alongside the CT scan may add value to the lung cancer screening program being rolled out. This study aims to explore the feasibility and utility of a lung cancer screening program with added heart and breathing tests within a single clinic visit.
A Lung Health Check will be offered to people at higher risk of lung cancer, specifically those aged 55-74 with a history of cigarette smoking. This will include a quick and painless LDCT scan, which uses a small amount of radiation to create detailed images of the lungs to detect lung cancer at an early and more treatable stage.
In this "GALACTIC-1" study, the investigators will explore whether structured reporting of the CT scan, combined with additional tests (blood sample, ECG heart trace, and spirometry breathing test), can help identify conditions such as chronic obstructive pulmonary disease (COPD), lung scarring (pulmonary fibrosis), coronary artery disease, heart failure, and early signs of bone fractures (osteoporosis). This enhanced Lung Health Check may improve overall health by identifying and allowing early management of these conditions.
The investigators plan to use the data from the "GALACTIC-1" study to explore AI performance by comparing it to reporting done by doctors. The results will help shape future rollout of lung cancer screening across Scotland, ensuring it is effective, efficient, and beneficial.
The investigators will also have a focus group with patients and interviews with NHS staff to understand their opinions on the screening.
Interested in participating?
Request Info55 year–74 year
All sexes
Interventional
Not applicable
Glasgow, United Kingdom
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Low dose Chest CT
Time frame: 6 months
Number of patients successfully screened per protocol within recruitment timelines
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Proportion of participants found to have lung cancer
Time frame: Baseline
The proportion detected at Stage I/II vs. Stage III/IV
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Baseline
Time frame: Year 1 and Year 2
Accessible health records, investigation requests, prescriptions, hospital admissions and survival at year 1 and year 2 post Galactic-1 clinic will be reviewed to determine the impact the LDCT had on the patient's care.
Time frame: Baseline
Number of radiology reports which agree with the AI report
Time frame: Baseline
Participant experience questionnaires will be collected during GALACTIC-1 clinic to provide an overview of experienced acceptability at the time of clinic attendance. Additional focus group or semi-structured interviews will be conducted.
Time frame: Year 2
Contact information is provided by the study sponsor or research team.
NHS Greater Glasgow and Clyde
Other
GALACTIC 1 - Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study
Acronym: GALACTIC-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05754801
Cancer, Neoplasms
Hong Kong
View Trial DetailsNCT05885048
Cancer, Effects of Immunotherapy
Bern, Switzerland
View Trial DetailsNCT05350761
Cancer, Environment
Bethesda, Maryland, United States
View Trial DetailsNCT07729969
Cancer, Cognition Disorders
Bilbao, Bizkaia, Spain
View Trial Details